Viatris Inc at Piper Sandler Healthcare Conference Transcript
Good morning, everyone. Let's kick things off. Welcome to the Piper Sandler Healthcare Conference. This is David Amsellem from the biopharma research team, and we're delighted to have Viatris with us. Lots to talk about. We have Doretta Mistras, CFO; and Philippe Martin, Chief R&D Officer. So thanks both of you for joining us.
So I'm going to fire away with lots of questions, and there's lots to talk about. But just starting at a high level, wanted to get your thoughts on capital deployment. Particularly interested in how aggressively you will look to pursue brand assets. That's been an increasingly visible theme at the company. And how do you balance that versus prioritizing the return of capital to shareholders?
Questions & Answers
Thanks, David. It's great to be here. So thanks for having us. From a capital allocation perspective, our philosophy has remained consistent. We want to be balanced and disciplined between kind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
